In model 2, adjusted HRs (95% CIs) for 96–100% versus 0–33% YKL-40 percentile category were 2.4 (1.6–3.7) for obesity-related cancers, 2.6 (1.7–4.1) for gastrointestinal cancers, 44.2 (12.8–153.4) for liver cancer, 1.8 (0.4–8.2) for pancreatic cancer, 0.6 (0.2–1.5) for colorectal cancer, 4.2 (1.3–14.1) for bladder cancer, and 1.5 (0.5–4.4) for lung cancer (Figs. 1–2, Supplemental Table 2). This evidence concerns the gene CHI3L1 and colorectal cancer.